These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38663646)

  • 1. Nanocarriers of antigen proteins for vaccine delivery.
    Lopes Chaves L; Dourado D; Prunache IB; Manuelle Marques da Silva P; Tacyana Dos Santos Lucena G; Cardoso de Souza Z; Muniz Mendes Freire de Moura P; Nunes Bordallo H; Rocha Formiga F; de Souza Rebouças J
    Int J Pharm; 2024 Jun; 659():124162. PubMed ID: 38663646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
    Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
    ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles and Vaccine Development.
    Kheirollahpour M; Mehrabi M; Dounighi NM; Mohammadi M; Masoudi A
    Pharm Nanotechnol; 2020; 8(1):6-21. PubMed ID: 31647394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine delivery systems toward lymph nodes.
    Ding Y; Li Z; Jaklenec A; Hu Q
    Adv Drug Deliv Rev; 2021 Dec; 179():113914. PubMed ID: 34363861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
    Gause KT; Wheatley AK; Cui J; Yan Y; Kent SJ; Caruso F
    ACS Nano; 2017 Jan; 11(1):54-68. PubMed ID: 28075558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine delivery carriers: insights and future perspectives.
    Correia-Pinto JF; Csaba N; Alonso MJ
    Int J Pharm; 2013 Jan; 440(1):27-38. PubMed ID: 22561794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
    Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
    Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
    [No Abstract]   [Full Text] [Related]  

  • 9. Nanovaccines : nanocarriers for antigen delivery.
    Gonzalez-Aramundiz JV; Cordeiro AS; Csaba N; de la Fuente M; Alonso MJ
    Biol Aujourdhui; 2012; 206(4):249-61. PubMed ID: 23419252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarriers: a versatile approach for mucosal vaccine delivery.
    Mody N; Sharma R; Agrawal U; Vyas SP
    Ther Deliv; 2015 Feb; 6(2):231-45. PubMed ID: 25690089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lignin nanoparticles as a promising vaccine adjuvant and delivery system for ovalbumin.
    Alqahtani MS; Kazi M; Ahmad MZ; Syed R; Alsenaidy MA; Albraiki SA
    Int J Biol Macromol; 2020 Nov; 163():1314-1322. PubMed ID: 32645499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticles as Adjuvants in Vaccine Delivery.
    Garg A; Dewangan HK
    Crit Rev Ther Drug Carrier Syst; 2020; 37(2):183-204. PubMed ID: 32865905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanogel-Mediated antigen delivery: Biocompatibility, immunogenicity, and potential for tailored vaccine design across species.
    Laura Soriano Pérez M; Montironi I; Alejandro Funes J; Margineda C; Campra N; Noelia Cariddi L; José Garrido J; Molina M; Alustiza F
    Vaccine; 2024 Jun; 42(17):3721-3732. PubMed ID: 38719694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems.
    Sharma S; Mukkur TK; Benson HA; Chen Y
    J Pharm Sci; 2009 Mar; 98(3):812-43. PubMed ID: 18661544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocarriers for systemic and mucosal vaccine delivery.
    Shahiwala A; Vyas TK; Amiji MM
    Recent Pat Drug Deliv Formul; 2007; 1(1):1-9. PubMed ID: 19075870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines.
    Benne N; van Duijn J; Kuiper J; Jiskoot W; Slütter B
    J Control Release; 2016 Jul; 234():124-34. PubMed ID: 27221070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advancement of gelatin nanoparticles in drug and vaccine delivery.
    Sahoo N; Sahoo RK; Biswas N; Guha A; Kuotsu K
    Int J Biol Macromol; 2015 Nov; 81():317-31. PubMed ID: 26277745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomaterials for nanoparticle vaccine delivery systems.
    Sahdev P; Ochyl LJ; Moon JJ
    Pharm Res; 2014 Oct; 31(10):2563-82. PubMed ID: 24848341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases.
    Bolhassani A; Javanzad S; Saleh T; Hashemi M; Aghasadeghi MR; Sadat SM
    Hum Vaccin Immunother; 2014; 10(2):321-32. PubMed ID: 24128651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.